

Upcoming Formulary Changes

BeneCard PBF is committed to providing innovative clinical solutions, valuable trend management strategies, and the highest quality of service. We regularly conduct a review of our formulary to remain current with the ever-changing prescription drug landscape.

During this review process, we consider changes that occur with new FDA approvals (brand and generic) and the latest clinical information. This comprehensive review looks at each therapeutic category to identify clinically superior products at the lowest net cost. This process is essential to help control pharmaceutical spend as drug costs, particularly for already costly specialty medications, increase over time. Our goal when considering updates to our formularies is to improve member health outcomes while maximizing plan savings.

January 2023 Changes

The following changes to the Primary Formulary will go into effect on January 1, 2023.

Moved from Non-Preferred to Preferred	Most Common Indication/Use
FULPHILA	Neutropenia
VEMLIDY 25MG	Hepatitis B

Moved from Preferred to Non-Preferred	Most Common Indication/Use
VAGIFEM	Menopause
VICTOZA	Type 2 Diabetes
NYVEPRIA	Neutropenia

BeneCard PBF appreciates your trust and support in serving your healthcare needs through your prescription benefit program. If you have any questions, please contact your BeneCard PBF Account Executive, or call our Client Service Center at 1-877-587-2239.